iqp-0528
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2017 (NCT03082690)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- iqp-0528
- iqp-0528
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03082690 | Phase 1 | May 15, 2017 | ImQuest Pharmaceuticals, Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImQuest Pharmaceuticals | For profit | 1 | 0 | 1 | 2017 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1